Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Xiaocen Kong, Menghui Luo, Ling Cai, Peng Zhang, Rengna Yan, Yun Hu, Huiqin Li & Jianhua Ma. (2021) Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system. Expert Opinion on Drug Delivery 18:5, pages 635-641.
Read now
Read now
Melanie Davies, Sudesna Chatterjee & Kamlesh Khunti. (2016) The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clinical Pharmacology: Advances and Applications 8, pages 61-81.
Read now
Read now
Charles F. Shaefer & John Anderson. (2016) The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin. Postgraduate Medicine 128:1, pages 137-144.
Read now
Read now
Gemma Sutton, Joan Minguet, Carmen Ferrero & Peter Bramlage. (2014) U300, a novel long-acting insulin formulation. Expert Opinion on Biological Therapy 14:12, pages 1849-1860.
Read now
Read now
Keith L Davis, Wenhui Wei, Juliana L Meyers, Brett S Kilpatrick & Naushira Pandya. (2014) Use of basal insulin and the associated clinical outcomes among elderly nursing home residents with type 2 diabetes mellitus: a retrospective chart review study. Clinical Interventions in Aging 9, pages 1815-1822.
Read now
Read now
Philip Levin, Wenhui Wei, Li Wang, Chunshen Pan, Damon Douglas & Onur Baser. (2012) Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Current Medical Research and Opinion 28:3, pages 439-446.
Read now
Read now
Andreas Holstein, Helger Stege & Peter Kovacs. (2010) Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opinion on Drug Safety 9:2, pages 225-231.
Read now
Read now
Articles from other publishers (27)
Megren H. A. Fagihi & Sourav Bhattacharjee. (2022) Amyloid Fibrillation of Insulin: Amelioration Strategies and Implications for Translation. ACS Pharmacology & Translational Science 5:11, pages 1050-1061.
Crossref
Crossref
Vaisnevee Sugumar, Kuan Ping Ang, Ahmed F. Alshanon, Gautam Sethi, Phelim Voon Chen Yong, Chung Yeng Looi & Won Fen Wong. (2022) A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method. Pharmaceutics 14:7, pages 1406.
Crossref
Crossref
Robert E. Shiel & Carmel T. Mooney. (2022) Insulins for the long term management of diabetes mellitus in dogs: a review. Canine Medicine and Genetics 9:1.
Crossref
Crossref
Hiroshi Miura, Kazuhiko Sakaguchi, Yuko Okada, Natsu Otowa-Suematsu, Tomoko Yamada, Anna So, Hisako Komada, Yushi Hirota, Minoru Kishi, Akihiko Takeda, Yoichi Tominaga, Tomoaki Nakamura, Yasuo Kuroki, Tomokazu Matsuda, Keiji Iida, Michiko Kajikawa, Takeshi Ohara, Kazuki Yokota, Kenta Hara, Sanshiro Tateya, Yoshikazu Tamori & Wataru Ogawa. (2018) Effects of Insulin Degludec and Insulin Glargine U300 on Day-to-Day Fasting Plasma Glucose Variability in Individuals with Type 1 Diabetes: A Multicenter, Randomized, Crossover Study (Kobe Best Basal Insulin Study 2). Diabetes Therapy 9:6, pages 2399-2406.
Crossref
Crossref
Goran Petrovski, Dashamir Gjergji, Aleksandra Grbic, Blazenko Vukovic, Mitja Krajnc & Natasa Grulovic. (2018) Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries. Diabetes Therapy 9:4, pages 1657-1668.
Crossref
Crossref
Arnaldo Moura Neto & Maria Tereza Martins Ferrari. (2018) Efficacy, safety and clinical use of newer basal insulins analogs. Endocrinology&Metabolism International Journal 6:3.
Crossref
Crossref
H. Q. Li, C. F. Lu, J. Wang, G. P. Yin, R. Sun, X. H. Xu, B. L. Liu, F. F. Li, T. Jing, K. O. Lee, L. Ye, J. H. Ma & X. F. Su. (2017) A comparison of clinical efficacy and economic value in Basalin- and Lantus-treated patients with type 2 diabetes using continuous glucose monitoring system. Journal of Endocrinological Investigation 41:2, pages 179-184.
Crossref
Crossref
Stephen Gough & Parth Narendran. 2017. Textbook of Diabetes. Textbook of Diabetes
399
413
.
Gaurav Puppalwar, Sandesh Sawant, Bhimsen Silgiri, Kirti Shukla & Hanmant Barkate. (2017) Evaluation of Safety and Efficacy of Glaritus<sup>®</sup> versus Lantus<sup>®</sup> in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study. Open Journal of Endocrine and Metabolic Diseases 07:04, pages 111-125.
Crossref
Crossref
Zhixia Li, Yuan Zhang, Xiaochi Quan, Zhirong Yang, Xiantao Zeng, Linong Ji, Feng Sun & Siyan Zhan. (2016) Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. PLOS ONE 11:5, pages e0154206.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
Günter Müller. 2016. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
3119
3166
.
G. Dailey & F. Lavernia. (2015) A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine. Diabetes, Obesity and Metabolism 17:12, pages 1107-1114.
Crossref
Crossref
Feng Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Yuan Zhang, Xiaochi Quan, Linong Ji & Siyan Zhan. (2015) Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice 110:1, pages 26-37.
Crossref
Crossref
Feng Sun, Shanshan Wu, Shuxia Guo, Kai Yu, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji & Siyan Zhan. (2014) Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis. Endocrine 48:3, pages 794-803.
Crossref
Crossref
Feng Sun, Shanshan Wu, Jing Wang, Shuxia Guo, Sanbao Chai, Zhirong Yang, Lishi Li, Yuan Zhang, Linong Ji & Siyan Zhan. (2015) Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Clinical Therapeutics 37:1, pages 225-241.e8.
Crossref
Crossref
Günter Müller. 2014. Drug Discovery and Evaluation: Pharmacological Assays. Drug Discovery and Evaluation: Pharmacological Assays
1
54
.
Tatsuhiko Urakami, Yusuke Naito & Yutaka Seino. (2014) Insulin glargine in pediatric patients with type 1 diabetes in Japan. Pediatrics International 56:6, pages 822-828.
Crossref
Crossref
S. Wu, F. Sun, Y. Zhang, Z. Yang, T. Hong, Y. Chen & S. Zhan. (2014) The cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials. Journal of Clinical Pharmacy and Therapeutics 39:1, pages 7-13.
Crossref
Crossref
V. Pandyarajan & M. A. Weiss. (2012) Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus. Current Diabetes Reports 12:6, pages 697-704.
Crossref
Crossref
Lora L Hamuro & Narendra S Kishnani. (2012) Metabolism of biologics: biotherapeutic proteins. Bioanalysis 4:2, pages 189-195.
Crossref
Crossref
Daniel F. Berenson, Allison R. Weiss, Zhu-li Wan & Michael A. Weiss. (2011) Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering. Annals of the New York Academy of Sciences 1243:1, pages E40-E54.
Crossref
Crossref
S. Arnolds, B. Kuglin, C. Kapitza & T. Heise. (2010) How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. International Journal of Clinical Practice 64:10, pages 1415-1424.
Crossref
Crossref
Wei-Xin Li, Jian-Feng Gou, Jin-Hui Tian, Xiang Yan & Lin Yang. (2010) Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Current Therapeutic Research 71:4, pages 211-238.
Crossref
Crossref
B. Charbonnel, E. Eschwège, G. Charpentier, B. Vialettes, G. Chabrier, D. Pouchain, S. Suissa, J. Massol & M. Lièvre. (2010) Insuline glargine en conditions réelles d’utilisation en France. Médecine des Maladies Métaboliques 4:2, pages 169-178.
Crossref
Crossref
Jaishree Kumari & T.S. Dharmarajan. (2009) Insulin Glargine Induced Persistent Intractable Hypoglycemia, with Variable Presentations in Older Diabetic Patients: An Experience of 4 Cases. Journal of the American Medical Directors Association 10:9, pages 672-673.
Crossref
Crossref
G. A. Thomson & R. Craig. (2009) Where now for insulin glargine - a time for pragmatic medicine?. International Journal of Clinical Practice 63:10, pages 1413-1415.
Crossref
Crossref